The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large ...
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...
Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...
The stock's early-sessions lows when it was down more than 10% had put it on track to be Amgen's (AMGN) worst one-day percentage fall since a 13.4% drop on Oct. 27, 2000, according to Dow Jones Market ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...
Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Poseida Therapeutics Inc. is being bought out for $1.5 billion by partner Roche Holdings Inc. to allogeneic CAR T therapies to treat hematologic malignancies. The two companies began their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback